1. Home /
  2. Investing /
  3. Cannabis

Cannabis  

One Way or Another, Cannabis Is on the Election Ballot

Cannabis investors are keenly aware of the landscape and how it could play out for the industry.

3 Cannabis Stock Plays to Consider

Let's take a close look at Canopy Growth, GrowGeneration and cannabis REIT Innovative Industrial Properties.

How to Play GrowGeneration as Triggers Approach

In a few years, online gambling and legal cannabis will be allowed in more places than they won't be.

GW Pharmaceuticals Could Bottom Out Into Year-End

The bear case is still intact.

Analyst Bets Compass' 'Magic Mushroom' Approach Is on the Button

Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target.

I'm Ringing the Register and Looking for the Next Potential Winners

This is a very healthy market and some consolidations and pullbacks would be advantageous for trading.

Cannabis Sales Are Recovering From Covid-19, but Just How Much Is Debatable

The available data don't paint a clear picture of the extent of the rebound in sales in different states.

Shark Bites: A Cannabis Play That Doesn't Sell Cannabis

Sometimes the best way to play a theme is with the 'pick and shovel' method.

What Were Those Analysts Smoking?

Just as we saw with pot stocks, if you play shares strictly because they're going up, you're likely to get burnt.

Among Cannabis Stocks, Here's a Breath of Fresh Ayr

Ayr Strategies is expanding in a contracting market.

Here's How to Make Sense of the Canopy Growth, Acreage Deal

The amended deal between the two cannabis companies is a doozy.

Just How Strong Are Constellation Brands' Charts?

I continue to recommend a reduced long exposure on STZ.

Investing in Cannabis? Don't 'Write Off' This Item

Publicly traded cannabis companies are expected to take big write downs on assets, and here's why it matters.

Constellation Brands Could Disappoint the Thirsty Bulls

Let's review the charts and indicators ahead of earnings.

Is Psilocybin the New CBD?

As psychedelic medicines begin to become decriminalized, psilocybin seems to be leading the way in this category.

Compass Pathways Takes Investors on a Trip to Higher Prices

Fresh off IPO, company sees mushrooming opportunity in psilocybin.

The Promise of Hemp Begins to Fade

There are huge problems now plaguing the industry, which was just beginning to recover from last year's oversupply issues.

Shark Bites: Trulieve Cannabis Is High on My List Into the Third Quarter

TCNNF is a 'seed-to-sale' company that offers 155 products.

Capital Raising in Cannabis Falls 67%

Only five companies went public during the first half of 2020 versus 13 in the first half of 2019.

Vape Recovery Goes Up in Smoke Amid Pandemic

Following widely reported lung injuries and bans, the products struggle to come back as concerns over Covid-19 burn on.

Bearish Bets: 2 Fragile-Looking Stocks You Should Consider Shorting This Week

These names are displaying both technical and quantitative deterioration.

My Shopping List Amid This Selloff

Don't be in a rush. The key to accumulating stocks in this environment is to move incrementally.

GrowGeneration Remains Ready to Sprout

A fresh look at the budding hydroponic supplier.

Are Harvest Health's Legal Problems a Red Flag?

While HRVSF has navigated through numerous changes and delivered solid revenue, litigation issues are piling up.

GrowGeneration on a Tear as the Cannabis Field Expands

GRWG has no meaningful competition. The companies in the space are one-third the size and not competing on the same national scale.

Saw Your Investments Go to Pot? Consider Cannabis Tech

Here are two tech-infused names to watch this year.

Canaccord Genuity Raises U.S. Cannabis Sales Outlook

Many in the cannabis industry have been surmising that states will look to cannabis to plug any budget shortfalls.

Will Mydecine's Move Make the Market for Pharmaceutical Psilocybin Mushroom?

Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.

Stock Picking Has Become Quite Difficult

The big question is how does this action resolve itself?

After Smoke Clears, Pot Industry Could See M&A Activity Light Up

Real Money tapped an industry expert to discuss the outlook for buying and selling of cannabis companies.